Datavault AI Inc. (NASDAQ: DVLT) has entered into a nonbinding letter of intent to acquire a 19.9% equity interest in DataMEDS AI Inc. (NASDAQ: MEDS) in exchange for expanding its existing technology license with the company. The proposed transaction would allow Datavault AI to retain ownership of its underlying intellectual property while potentially generating royalty revenue from commercialization of the licensed technologies. DataMEDS would assume commercialization costs, and Datavault AI would have the right to designate one director to the DataMEDS board following closing.
The company believes a fourth-quarter 2026 closing is achievable, subject to due diligence, definitive agreements and customary closing conditions. The proposed expanded license would build on DataMEDS’ existing PharmacyChain platform and EinsteinRx AI capabilities, incorporating Datavault AI Health technologies designed to support patient-controlled health data access, management, monetization and tokenization across pharmacy, laboratory, wearable and other health care environments. The initiative is part of broader efforts by DataMEDS to expand its health care technology capabilities through arrangements with several companies, including EOS Technology Holdings, Scilex Holding Company, HealthBridge Advisors and REBOOT Health AI. The letter of intent does not obligate either party to complete the transaction.
The deal matters because it offers a template for how AI and data-focused companies can monetize proprietary technology without selling it outright. By taking equity instead of a straight licensing fee, Datavault AI aligns its upside with DataMEDS’ commercialization success while keeping control of its core intellectual property. For investors, the arrangement could mean royalty revenue with lower operational risk, as DataMEDS bears the cost of bringing the technology to market. The board seat also gives Datavault AI a voice in how its technology is deployed in health care settings, where patient data privacy and regulatory scrutiny are intense.
The health data market is attracting significant attention as companies seek to give patients more control over their information while enabling secure monetization. Datavault AI’s proposed expanded license would incorporate its Health technologies into DataMEDS’ PharmacyChain and EinsteinRx platforms, potentially creating a more comprehensive offering for pharmacies, laboratories and wearable device makers. If successful, the collaboration could position both companies to capture a share of the growing demand for patient-centric data solutions.
However, the nonbinding nature of the letter of intent means there is no guarantee the transaction will close. Due diligence, definitive agreements and customary closing conditions must all be satisfied, and the targeted fourth-quarter 2026 closing leaves ample time for the deal to fall apart. Investors should weigh the potential benefits against the execution risk. For more details on Datavault AI, visit https://dvlt.ai. The full press release is available at https://ibn.fm/Q8IGK, and additional news can be found in the company’s newsroom at https://ibn.fm/DVLT.
The announcement was distributed through DefenseWireNews, part of the Dynamic Brand Portfolio at IBN, which provides InvestorWire distribution and editorial syndication to 5,000+ outlets. For full disclaimers, see https://www.DefenseWireNews.com/Disclaimer.
